Show Notes
Ten years after it was spun out of MIT, Invivo Thereapeutics and its neuro scaffold treatment for traumatic spinal cord injuries is moving closer to a reality. The company has completed enrollment of its 5 patient pilot study, which has made headlines around the world and is looking to push forward on adding more patients. In this episode of DeviceTalks, we talk to new CEO Mark Perrin about the company and why there has been so little movement in the fight against paralysis.
